` ABVX (Abivax SA) vs DAX Index Comparison - Alpha Spread

ABVX
vs
D
DAX Index

Over the past 12 months, ABVX has significantly outperformed DAX Index, delivering a return of +1 177% compared to the DAX Index's +19% growth.

Stocks Performance
ABVX vs DAX Index

Loading
ABVX
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ABVX vs DAX Index

Loading
ABVX
DAX Index
Difference
www.alphaspread.com

Performance By Year
ABVX vs DAX Index

Loading
ABVX
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Abivax SA vs Peers

DAX Index
ABVX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Abivax SA
Glance View

Market Cap
7.4B EUR
Industry
Biotechnology

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

ABVX Intrinsic Value
12.95 EUR
Overvaluation 86%
Intrinsic Value
Price
Back to Top